Clinical Trial Update: A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating vestipitant (GW597599) for breakthrough postoperative nausea and vomiting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Nausea and Vomiting

Drugs mentioned

• Vestipitant (vestipitant)

Snippet

Sponsor: Accenture | Conditions: Postoperative Nausea and Vomiting | Phase 2 | Status: COMPLETED